{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T13:55:25Z","timestamp":1773842125462,"version":"3.50.1"},"reference-count":26,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2006,4,25]],"date-time":"2006-04-25T00:00:00Z","timestamp":1145923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Gastro and Hepatol"],"published-print":{"date-parts":[[2006,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background and Aim:\u2002<\/jats:bold> The survival of patients with unresectable advanced hepatocellular carcinoma (HCC) with portal vein thrombosis is dismal. Current therapeutic options have limited efficacy. Vitamin K has been shown to have antitumor effect on HCC cells both in cell lines and patients with advanced HCC. The aim of this study was to assess the clinical efficacy of high dose vitamin K3 in the treatment of advanced HCC with portal vein thrombosis.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> Forty\u2010two consecutive patients with advanced HCC (Stage C according to BCLC staging system) with portal vein thrombosis were randomized into two groups: (i) high dose vitamin K3 (<jats:italic>n<\/jats:italic>\u2003=\u200323); and (ii) placebo (<jats:italic>n<\/jats:italic>\u2003=\u200319). The vitamin K3 was administered by i.v. infusion of 50\u2003mg\/day with daily increase of dose by 50\u2003mg for 6\u2003days, followed by 20\u2003mg i.m. twice daily for 2\u2003weeks.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Of the 23 patients treated with vitamin K, one (4.3%) achieved complete response and three (13%) partial response, for a total of four (17.4%) objective responders overall. The overall mean survival was 8.9\u2003\u00b1\u20038.8\u2003months (median: 6; range 1\u201337\u2003months) in the vitamin K group and 6.8\u2003\u00b1\u20035.3\u2003months (median: 5; range 1.5\u201321\u2003months) in the placebo group (<jats:italic>P\u2003<\/jats:italic>=\u20030.552). The mean duration of survival was longer in patients in the vitamin K group who achieved objective response (22.5\u2003\u00b1\u200312.2; median: 21; range 11\u201337\u2003months) as compared to patients not achieving objective response (6.1\u2003\u00b1\u20034.6; median: 5; range 1\u201316\u2003months) (<jats:italic>P\u2003<\/jats:italic>=\u20030.0.002). Portal vein thrombosis resolved with complete patency in one (4.35%) patient.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> Treatment with high dose vitamin K produces objective response in 17% patients with improved survival in patients achieving objective response; however, it does not affect the overall survival.<\/jats:p>","DOI":"10.1111\/j.1440-1746.2006.04383.x","type":"journal-article","created":{"date-parts":[[2006,4,25]],"date-time":"2006-04-25T16:14:57Z","timestamp":1145981697000},"page":"1478-1482","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["High dose vitamin K3 infusion in advanced hepatocellular carcinoma"],"prefix":"10.1111","volume":"21","author":[{"given":"Shiv K","family":"Sarin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed","family":"Hissar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandana","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barjesh C","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,28]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1007117"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.32089"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.34.11.1598"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(20000501)88:9<1986::AID-CNCR2>3.0.CO;2-I"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880801)62:3<479::AID-CNCR2820620306>3.0.CO;2-L"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2001.02352.x"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.35071"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510310111"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(95)90402-6"},{"key":"e_1_2_5_11_2","first-page":"713","article-title":"Antitumor effects of vitamins K1, K2 and K3 on hepatocellular carcinoma in vitro and in vivo","volume":"26","author":"Hitomi M","year":"2005","journal-title":"Int. J. Oncol."},{"key":"e_1_2_5_12_2","first-page":"1337","article-title":"In vitro and in vivo antitumor effects of vitamin K5 on hepatocellular carcinoma","volume":"26","author":"Hitomi M","year":"2005","journal-title":"Int. J. Oncol."},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20260"},{"key":"e_1_2_5_14_2","first-page":"A1485","article-title":"Vitamin K (VK) inhibits hepatoma cell growth in vitro and in patients [Meeting abstract]","volume":"37","author":"Carr BI","year":"1996","journal-title":"Proc. AACR"},{"key":"e_1_2_5_15_2","first-page":"348A","article-title":"Suppression of DCP\/PIVKA\u20102 and alpha\u2010fetoprotein levels in human hepatocellular carcinoma (HCC) by high doses of vitamin K1 (VK1)","volume":"22","author":"Carr BI","year":"1996","journal-title":"Hepatology"},{"key":"e_1_2_5_16_2","first-page":"278A","article-title":"A phase I\/phase II study of high dose vitamin K (VK) to patients with advanced inoperable hepatocellular carcinoma (HCC): interim analysis","volume":"20","author":"Carr BI","year":"1994","journal-title":"Hepatology"},{"key":"e_1_2_5_17_2","first-page":"1182","article-title":"Phase II study of high\u2010dose vitamin K1 in hepatocellular carcinoma: a GISCAD study","volume":"17","author":"Zaniboni A","year":"1998","journal-title":"ASCO"},{"key":"e_1_2_5_18_2","first-page":"16","article-title":"Vitamin K cuts hepatocellular carcinoma mortality","volume":"32","author":"Jancin B","year":"2002","journal-title":"Fam. Pract. News"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(93)90469-J"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1007122"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0009-2797(88)90052-X"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1202748"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1006\/bioo.1996.1052"},{"key":"e_1_2_5_25_2","first-page":"80","article-title":"Vitamin K3 induces cell death by inhibiting dual specificity phosphatases","volume":"40","author":"Chyan C\u2010L","year":"1999","journal-title":"Proc. AACR"},{"key":"e_1_2_5_26_2","first-page":"3240","article-title":"Effect of two antitumor derivatives of vitamin K on cell cycle regulating proteins in human hepatoma HepG2 cells","volume":"40","author":"Markovits J","year":"1999","journal-title":"Proc. AACR"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1053\/hupa.2001.23524"}],"container-title":["Journal of Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1746.2006.04383.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1746.2006.04383.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T10:38:21Z","timestamp":1697366301000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1746.2006.04383.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7,28]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["10.1111\/j.1440-1746.2006.04383.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1746.2006.04383.x","archive":["Portico"],"relation":{},"ISSN":["0815-9319","1440-1746"],"issn-type":[{"value":"0815-9319","type":"print"},{"value":"1440-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7,28]]},"assertion":[{"value":"2006-07-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}